HOME > TOP STORIES

TOP STORIES

BUSINESS Aiming for 6% Yearly Growth by Rivaroxaban Launching: Bayer AG

October 6, 2011
REGULATORY Number of Pharmacies Qualifying for Premiums for GE Drug Dispensing Systems Down in 2010

October 6, 2011
BUSINESS Takeda President Hasegawa Says Innovation Will Take Place in Developing Countries

October 5, 2011
BUSINESS Ono and Germany’s Merck Enter into License Agreements to Boost Priority Fields

October 5, 2011
ORGANIZATION Leading Biotech Clusters in Osaka, Munich Sign Partnership Agreement

October 5, 2011
REGULATORY FPMAJ States Difficulty in Identifying Anticancer Drugs in Terms of Adverse Reactions

October 4, 2011
BUSINESS Mochida’s New 3-Year Business Plan Aims for Sales of ¥100 Bil. in FY2013

October 4, 2011
BUSINESS Takeda Completes Acquisition of Nycomed, Global Rx Sales Ranking Up to 12th

October 3, 2011
ORGANIZATION Takeda “Will Be Able to Get Through” Power Shortages: Mr Hasegawa

October 3, 2011
ORGANIZATION “Permanent Introduction of Premium for New Drug Development Premature”: CSIMC Member Adachi

September 30, 2011
BUSINESS MS Pharma Forms Strategic Alliance with Korean Company in Biosimilars

September 30, 2011
BUSINESS Takeda President Hasegawa Eyes Joint Research with Chinese Companies

September 29, 2011
REGULATORY CSIMC’s Committee to Assess Premium for New Drug Development Based on Results of Market Price Survey

September 29, 2011
BUSINESS MTPC to Start PIII Trial for Telaprevir in China Early 2012

September 29, 2011
ORGANIZATION JPMA Head Says Industry Will Support Infrastructure Development for Innovative Drug Discovery

September 28, 2011
BUSINESS Astellas Pharma Debuts on DJSI Asia Pacific Index

September 28, 2011
BUSINESS BMS to File for Apixaban for Stroke Prevention in Japan, US, and Europe Before Year-end

September 27, 2011
ORGANIZATION Continuation of Premium for New Drug Development to Depend on Effects on Drug Lag, Drug Development: Mr Shirakawa of Kenporen

September 26, 2011
REGULATORY 6 APIs/10 Products Including EpiPen Added to NHI Price List

September 22, 2011
BUSINESS Novartis Grows 7% Driven by New Products: President Mitani

September 22, 2011

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…